AML Extended Panel: Flowcytometry + Bone Marrow Karyotyping + FISH for 5 Markers + FLT3 Gene Mutation

The AML Extended Panel is essential for diagnosing AML, determining the risk level of the disease, and guiding treatment decisions. It helps doctors understand the complex genetic makeup of AML and tailor a treatment plan according to the patient’s specific condition.

Flow cytometry is a laboratory technique used to measure the physical and chemical characteristics of cells. In AML, flow cytometry is used to identify abnormal leukemia cells based on the presence of specific markers on their surface. This information is crucial for diagnosing AML and differentiating it from other types of leukemia.

Karyotyping is the process of examining chromosomes in a sample of cells. In AML, karyotyping of bone marrow cells can reveal abnormalities in the number or structure of chromosomes, which can provide insights into the aggressiveness and prognosis of the disease.

FISH (Fluorescence In Situ Hybridization) is a test that uses fluorescent probes to detect specific DNA sequences in chromosomes. It is used to identify chromosomal abnormalities and gene mutations that are common in AML. This information is valuable for risk stratification and treatment planning.

FLT3 is a gene often found to be mutated in AML. The presence of FLT3 mutations is associated with a more aggressive form of AML and can affect treatment response. Knowing the FLT3 mutation status can guide treatment decisions.

No, there is no need to fast before taking the AML Extended Panel.

The sample is usually collected from the blood or bone marrow. The bone marrow sample is typically collected through a bone marrow aspiration procedure.

Normal results would indicate the absence of the specific chromosomal abnormalities and gene mutations associated with AML. However, interpretation should be done by a doctor who will consider the patient's overall clinical picture.

If your test results are abnormal, it is important to consult your doctor to discuss the next steps. Your doctor will interpret the results and may recommend additional testing or treatment options.

The frequency of this test depends on the clinical status of the patient. It is usually done at diagnosis, and may be repeated during treatment to monitor the disease.

Yes, the AML Extended Panel can help predict disease progression. The genetic and cellular information provided can indicate how aggressive the leukemia is and how likely it is to respond to treatment.

Factors such as medication use, infections, and other underlying health conditions can affect the results of this test.

You should consult a hematologist or oncologist if your AML Extended Panel results are abnormal.

No, this test can also be used for patients undergoing treatment to monitor disease progression and treatment response.

Yes, the AML Extended Panel can be used to monitor the effectiveness of treatment by tracking changes in cellular characteristics and genetic markers over time.

Acquiring a deeper understanding of the genetic and cellular makeup of AML through the AML Extended Panel plays a significant role in managing this condition effectively. The combination of flow cytometry, karyotyping, FISH, and FLT3 mutation analysis provides a comprehensive assessment that is indispensable in diagnosis, risk assessment, and making informed treatment decisions. It is important for patients to discuss the findings and implications of this test with their doctor to develop a personalized treatment plan adapted to the specific characteristics of their disease. Regular monitoring through the AML Extended Panel is also key in evaluating the effectiveness of treatment and making necessary modifications.